Christopher W Kahler1, Patricia A Cioe1, Golfo K Tzilos2, Nichea S Spillane3, Lorenzo Leggio1,4, Susan E Ramsey5,6, Richard A Brown7, Stephanie S O'Malley8. 1. Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, Rhode Island. 2. Department of Family Medicine, University of Michigan, Ann Arbor, Michigan. 3. Department of Psychology, University of Rhode Island, South Kingston, Rhode Island. 4. Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, Bethesda, Maryland. 5. Department of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University and Rhode Island Hospital, Providence, Rhode Island. 6. Department of Medicine, The Warren Alpert Medical School of Brown University and Rhode Island Hospital, Providence, Rhode Island. 7. University of Texas at Austin, Austin, Texas. 8. Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Abstract
BACKGROUND: Post hoc analyses of 2 randomized controlled trials suggest naltrexone may reduce alcohol use and improve smoking cessation outcomes among heavy drinkers receiving smoking cessation treatment. However, no studies have been conducted specifically to examine naltrexone for this purpose or to test whether naltrexone has benefit when added to smoking cessation counseling that explicitly addresses heavy drinking. METHODS: We recruited heavy-drinking smokers from the community and randomized them to receive 10 weeks of either (i) 50 mg naltrexone (n = 75) or (ii) placebo (n = 75) daily. Participants received 6 weeks of transdermal nicotine patch and 6 sessions of counseling that addressed both heavy drinking and smoking. Participants were followed for 26 weeks after their target quit smoking date. RESULTS: Across medication conditions, there were substantial reductions at follow-up in percent heavy drinking days (primary outcome) and average drinks per week (secondary outcome). However, participants receiving naltrexone did not differ significantly from those receiving placebo on percent heavy drinking days (effect size d = -0.04, 95% CI [-0.30, 0.22], p = 0.76) or average drinks per week (d = -0.09, 95% CI [-0.35, 0.18], p = 0.54) during follow-up. Naltrexone compared to placebo was not associated with a significant increase in smoking abstinence rates during follow-up, odds ratio = 0.93, 95% CI [0.46, 1.86], p = 0.83. The effect of naltrexone on these outcomes was not significantly moderated by current alcohol dependence or gender. CONCLUSIONS: Results indicate that heavy-drinking smokers, including those with current alcohol dependence, can make substantial reductions in drinking in the context of smoking cessation treatment. However, this study provided no evidence that naltrexone is efficacious for enhancing reductions in drinking or improving smoking cessation in this population. Limitations of this study included lower-than-desired sample size and modest adherence to study medication.
RCT Entities:
BACKGROUND: Post hoc analyses of 2 randomized controlled trials suggest naltrexone may reduce alcohol use and improve smoking cessation outcomes among heavy drinkers receiving smoking cessation treatment. However, no studies have been conducted specifically to examine naltrexone for this purpose or to test whether naltrexone has benefit when added to smoking cessation counseling that explicitly addresses heavy drinking. METHODS: We recruited heavy-drinking smokers from the community and randomized them to receive 10 weeks of either (i) 50 mg naltrexone (n = 75) or (ii) placebo (n = 75) daily. Participants received 6 weeks of transdermal nicotine patch and 6 sessions of counseling that addressed both heavy drinking and smoking. Participants were followed for 26 weeks after their target quit smoking date. RESULTS: Across medication conditions, there were substantial reductions at follow-up in percent heavy drinking days (primary outcome) and average drinks per week (secondary outcome). However, participants receiving naltrexone did not differ significantly from those receiving placebo on percent heavy drinking days (effect size d = -0.04, 95% CI [-0.30, 0.22], p = 0.76) or average drinks per week (d = -0.09, 95% CI [-0.35, 0.18], p = 0.54) during follow-up. Naltrexone compared to placebo was not associated with a significant increase in smoking abstinence rates during follow-up, odds ratio = 0.93, 95% CI [0.46, 1.86], p = 0.83. The effect of naltrexone on these outcomes was not significantly moderated by current alcohol dependence or gender. CONCLUSIONS: Results indicate that heavy-drinking smokers, including those with current alcohol dependence, can make substantial reductions in drinking in the context of smoking cessation treatment. However, this study provided no evidence that naltrexone is efficacious for enhancing reductions in drinking or improving smoking cessation in this population. Limitations of this study included lower-than-desired sample size and modest adherence to study medication.
Authors: Jon Morgenstern; Alexis N Kuerbis; Andrew C Chen; Christopher W Kahler; Donald A Bux; Henry R Kranzler Journal: J Consult Clin Psychol Date: 2012-05-21
Authors: Benjamin A Toll; Steve Martino; Stephanie S O'Malley; Lisa M Fucito; Sherry A McKee; Christopher W Kahler; Alana M Rojewski; Martin C Mahoney; Ran Wu; Paula Celestino; Srinivasa Seshadri; James Koutsky; Andrew Hyland; K Michael Cummings Journal: J Consult Clin Psychol Date: 2014-11-24
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Robert F Leeman; Sherry A McKee; Benjamin A Toll; Suchitra Krishnan-Sarin; Judith L Cooney; Robert W Makuch; Stephanie S O'Malley Journal: Nicotine Tob Res Date: 2008-12 Impact factor: 4.244
Authors: Cassie M Chandler; Sarah E Maggio; Hui Peng; Kimberly Nixon; Michael T Bardo Journal: Drug Alcohol Depend Date: 2020-04-25 Impact factor: 4.492
Authors: Joshua L Karelitz; Erin A McClure; Caitlin Wolford-Clevenger; Lauren R Pacek; Karen L Cropsey Journal: Drug Alcohol Depend Date: 2021-02-03 Impact factor: 4.492
Authors: Lisa M Fucito; Ran Wu; Stephanie S O'Malley; Tess H Hanrahan; Jolomi T Ikomi; Srinivas Muvvala; Kathleen M Carroll; Ralitza Gueorguieva Journal: J Smok Cessat Date: 2020-03-18
Authors: Lara A Ray; ReJoyce Green; Craig Enders; Adam M Leventhal; Erica N Grodin; Gang Li; Aaron Lim; Emily Hartwell; Alex Venegas; Lindsay Meredith; Steven J Nieto; Steven Shoptaw; Diana Ho; Karen Miotto Journal: Am J Psychiatry Date: 2021-06-03 Impact factor: 19.242
Authors: Aaron C Lim; Kelly E Courtney; Nathasha R Moallem; Vincent C Allen; Adam M Leventhal; Lara A Ray Journal: Front Psychiatry Date: 2018-08-10 Impact factor: 4.157